United Rentals Introduces Workspace Ready Solutions
Workspace Ready Solutions take the burden off contractors by eliminating the need to outfit jobsite offices themselves. When project managers rent a mobile office trailer or container office, they can select from an extensive list of accessories, and United Rentals ensures the office is fully equipped and ready for use upon delivery.
Available accessories include construction site office furniture such as desks, chairs, filing cabinets and conference tables, as well as whiteboards, markers and other supplies. Appliances like refrigerators, coffee makers and microwaves are also available. United Rentals offers multiple packages and bundles, allowing companies to select exactly what they need and easily scale as project requirements evolve.
For storage containers, United Rentals provides add-ons including ramps, shelves, hooks, locks and solar lighting, offering secure and organized storage solutions.
'Project mobilization is a complex undertaking,' said Tom Jones, Senior Vice President – Operations, United Rentals. 'Project managers face countless tasks as they prepare jobsites, including securing temporary infrastructure like mobile office trailers and container offices. Our Workspace Ready Solutions give them a simple, efficient way to turn empty spaces into fully functional work environments.'
Workspace Ready Solutions are part of United Rentals' turnkey mobile office and accessories offerings. Contractors can rely on United Rentals for a full range of solutions, including mobile offices, storage containers, climate control, portable toilets, ground protection mats, heavy equipment, and temporary structures used as break rooms or warehouses. To learn more visit unitedrentals.com/solutions/specialty-solutions/storage-containers-mobile-offices/workspace-ready-solutions.
About United Rentals
United Rentals, Inc. is the largest equipment rental company in the world. The company has an integrated network of 1,601 rental locations in North America, 39 in Europe, 38 in Australia and 19 in New Zealand. In North America, the company operates in 49 states and every Canadian province. The company's approximately 27,300 employees serve construction and industrial customers, utilities, municipalities, homeowners and others. The company offers a fleet of equipment for rent with a total original cost of $21.21 billion. United Rentals is a member of the Standard & Poor's 500 Index, the Barron's 400 Index and the Russell 3000 Index® and is headquartered in Stamford, Conn. Additional information about United Rentals is available at unitedrentals.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
25 minutes ago
- Associated Press
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--Jul 8, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors. 'Raju has been an integral part of PureTech's journey for almost two decades, and we are deeply grateful for his dedication and leadership,' said Bharatt Chowrira, PhD, JD, PureTech's Chief Executive Officer. 'On behalf of the board, I'd like to wish Raju all the best in his future endeavors.' PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as Interim Chair of the Board of Directors. In collaboration with the Nominating Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the Board of Directors and will engage with shareholders to gather input on the criteria and overall board evolution as part of the process. Robert Langer, ScD, PureTech's Co-founder and member of the board said, 'Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry. It has been an honor and a privilege to serve alongside Raju for so many years at PureTech. I speak for the entire board in thanking him for his many years of dedication and his outstanding contributions.' During his tenure on the board, Dr. Kucherlapati helped guide PureTech from its startup phase into an established biotherapeutics company, which has an industry-leading track record of advancing breakthrough medicines, such as the recently FDA-approved Cobenfy™, and launching innovative Founded Entities, most recently, Seaport Therapeutics. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our intention to initiate a process to identify a new Chair of the Board of Directors, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or source version on CONTACT: PureTech Investor Relations [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH OTHER HEALTH SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 07/08/2025 12:45 PM/DISC: 07/08/2025 12:46 PM
Associated Press
25 minutes ago
- Associated Press
Axalta Schedules Second Quarter 2025 Earnings Conference Call
PHILADELPHIA, July 08, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, will release its second quarter 2025 financial results at 6 a.m. ET on Wednesday, July 30. The release and supporting materials will be posted to Axalta's Investor Relations site. In addition, the company will host a conference call at 8 a.m. ET on July 30. Chris Villavarayan, Chief Executive Officer and President, and Carl Anderson, Senior Vice President and Chief Financial Officer, will review the company's financial performance for the period. A live webcast of the conference call will be available here. A replay of the webcast will be posted shortly after the call and will remain accessible through July 30, 2026. The dial-in phone number for the conference call is 1-800-225-9448 and the conference ID is AXALTA. For those unable to participate, a replay of the call will be available through August 6, 2025. The replay dial-in number is 1-844-512-2921. The replay passcode is 11159306. About Axalta Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful, and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity, and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information, visit and follow us on LinkedIn.
Business Wire
30 minutes ago
- Business Wire
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors. "Raju has been an integral part of PureTech's journey for almost two decades, and we are deeply grateful for his dedication and leadership,' said Bharatt Chowrira, PhD, JD, PureTech's Chief Executive Officer. 'On behalf of the board, I'd like to wish Raju all the best in his future endeavors.' PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as Interim Chair of the Board of Directors. In collaboration with the Nominating Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the Board of Directors and will engage with shareholders to gather input on the criteria and overall board evolution as part of the process. Robert Langer, ScD, PureTech's Co-founder and member of the board said, 'Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry. It has been an honor and a privilege to serve alongside Raju for so many years at PureTech. I speak for the entire board in thanking him for his many years of dedication and his outstanding contributions.' During his tenure on the board, Dr. Kucherlapati helped guide PureTech from its startup phase into an established biotherapeutics company, which has an industry-leading track record of advancing breakthrough medicines, such as the recently FDA-approved Cobenfy™, and launching innovative Founded Entities, most recently, Seaport Therapeutics. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our intention to initiate a process to identify a new Chair of the Board of Directors, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
